Order Article Reprints

Hara T, Yamagami H, Uemoto R, Sekine A, Kaneko Y, Miyataka K, Hori T, Ichimura-Shimizu M, Funamoto M, Harada T, et al. Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice. Antioxidants. 2025; 14(7):891. https://doi.org/10.3390/antiox14070891

Hara, Tomoyo, Hiroki Yamagami, Ryoko Uemoto, Akiko Sekine, Yousuke Kaneko, Kohsuke Miyataka, Taiki Hori, Mayuko Ichimura-Shimizu, Masafumi Funamoto, Takeshi Harada, and et al. 2025. "Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice" Antioxidants 14, no. 7: 891. https://doi.org/10.3390/antiox14070891

Hara, T., Yamagami, H., Uemoto, R., Sekine, A., Kaneko, Y., Miyataka, K., Hori, T., Ichimura-Shimizu, M., Funamoto, M., Harada, T., Yuasa, T., Nakamura, S., Endo, I., Matsuoka, K.-i., Kawano, Y., Tsuneyama, K., Ikeda, Y., & Aihara, K.-i. (2025). Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice. Antioxidants, 14(7), 891. https://doi.org/10.3390/antiox14070891